Product Images Eliquis

This is a description of a medication called ELIQUIS (APIXABAN) 5MG, containing 14 tablets, with a lot number of 774738X1 and an expiration date of 05/23. The recommended adult dosage is contained in the package insert. The manufacturer is Bristol-Myers Squibb Company located in Princeton, NJ, and the product is distributed by Redpharm Drug in Eden Prairie, MN. The medication should be stored at a controlled room temperature of 20-25 C (68-77 F).*

The text contains information about Eliquis (Apixaban) tablets, including the NDC, dosage, lot number, and expiration date. It also provides instructions to store the medication at room temperature and to refer to the package insert for the recommended adult dosage. The manufacturer, Bristol-Myers Squibb Company, and distributor, Redpharm Drug, are listed along with their locations. The second section of text appears to contain similar information for a larger quantity of tablets in a different lot, also with a recommendation to store at room temperature and to refer to the package insert for the usual adult dosage.*

This appears to be a table with information related to various subgroups of patients in a study comparing Apixaban and Warfarin for treating a medical condition. The information includes the number of events and number of patients per year and hazard ratio between the two medications. Additionally, there is information on subgroups based on various criteria such as age, weight, stroke or TIA history, diabetes, creatinine clearance, geographic region, and whether randomized or not. However, the exact medical condition, purpose of the study, and other relevant details are not mentioned.*

Not available.*

This is a table showing the fold change and 90% confidence interval of interacting drugs with P-gp and strong CYP3A4 inhibitors, other CYP3A4 and P-gp inhibitors, and P-gp and strong CYP3A4 inducers. The drugs include Ketoconazole, Glarithromycin, Diltiazem, Naproxen, and Rifampin. The table provides information on the AUC (area under the curve) for each drug at different doses. It also shows the change relative to the reference drug.*

This is a medication dosing guide that provides recommendations on dose adjustments based on various population descriptions such as renal or hepatic impairment, age and body weight. It includes fold changes and 90% confidence intervals for PK. The guide suggests if no dose adjustment is needed or if a dosing recommendation can't be provided.*